Literature DB >> 8541560

Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment.

E Soll1, C Massumoto, R A Clift, C D Buckner, F R Appelbaum, R Storb, G Sale, R Hackman, P Martin.   

Abstract

A retrospective study compared posttransplant engraftment parameters in 203 patients with myelofibrosis (MF) with those in a population of 203 matched controls without MF. There were no significant differences between these groups in the proportions of patients who died without achieving engraftment and in the disease-free survival distributions. Furthermore, comparisons between the two groups of patients reaching the respective endpoints showed no differences in the time distributions for reaching 0.5 or 1.0 x 10(9)/L granulocytes, but the time to platelet transfusion independence was 3 days longer in patients with MF. In further analysis, results for 33 patients with severe MF were compared with those of their respective controls. The proportions of patients with severe MF who died without reaching these engraftment endpoints and the disease-free survival distributions in the two groups were similar. Among patients who reached the respective engraftment endpoints, there was no statistically significant difference in the pace of granulocyte recovery. In patients with severe MF, there was a 7-day delay in the time to reach platelet transfusion independence and a 2-day delay in the time to reach red blood cell independence, but the differences were not statistically significant. The present results do not substantiate concerns raised by earlier studies. MF may delay the time to reach platelet independence by approximately 3 days and may increase platelet transfusion requirements, but no other perturbation of hematopoietic reconstitution was apparent.

Entities:  

Mesh:

Year:  1995        PMID: 8541560

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis.

Authors:  Nicolaus Kröger; Tatjana Zabelina; Anja van Biezen; Ronald Brand; Dietger Niederwieser; Rodrigo Martino; Zi Yi Lim; Francesco Onida; Christoph Schmid; Laurent Garderet; Marie Robin; Michael van Gelder; Reinhard Marks; Argiris Symeonidis; Guido Kobbe; Theo de Witte
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

2.  Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis.

Authors:  H Alchalby; D-R Yunus; T Zabelina; F Ayuk; N Kröger
Journal:  Bone Marrow Transplant       Date:  2016-04-18       Impact factor: 5.483

Review 3.  Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia.

Authors:  William J Hogan; Mark R Litzow; Ayalew Tefferi
Journal:  Curr Hematol Malig Rep       Date:  2007-02       Impact factor: 3.952

Review 4.  Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis.

Authors:  Haefaa Alchalby; Nicolaus Kröger
Journal:  Curr Hematol Malig Rep       Date:  2010-04       Impact factor: 3.952

Review 5.  Allogeneic hematopoietic cell transplantation for patients with myelofibrosis.

Authors:  Dae Young Zang; H Joachim Deeg
Journal:  Curr Opin Hematol       Date:  2009-03       Impact factor: 3.284

6.  Early Mixed Lymphoid Donor/Host Chimerism is Associated with Improved Transplant Outcome in Patients with Primary or Secondary Myelofibrosis.

Authors:  H Joachim Deeg; Rachel B Salit; Tim Monahan; Gary Schoch; Chris McFarland; Bart L Scott; Barry E Storer
Journal:  Biol Blood Marrow Transplant       Date:  2020-07-18       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.